Related Experiment Video
Updated: Apr 20, 2026

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
Published on: March 1, 2024
What have we learned about genetic susceptibility in psoriasis and psoriatic arthritis?
Lihi Eder1, Vinod Chandran, Dafna D Gladman
1Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada.
Purpose Of Review:
To review recent evidence for genetic susceptibility in psoriasis and psoriatic arthritis.
Recent Findings:
Psoriasis and psoriatic arthritis (PsA) have substantive genetic determinants as indicated by their high family aggregation. Psoriasis and PsA share several susceptibility genes; however, other genes, mostly within the major histocompatibility complex (MHC) region, confer an independent risk for PsA. The human leukocyte antigen-C0602 allele confers the highest risk for psoriasis whereas several human leukocyte antigen-B alleles were identified as 'PsA-specific' genes. Fine mapping of the MHC suggests that glutamine at position 45 is an important susceptibility factor for PsA. Additional genes outside of the MHC region were identified as psoriasis susceptibility genes. These genes belong to several proinflammatory pathways and skin barrier mechanisms that play a role in the pathogenesis of psoriatic disease.
Summary:
The MHC remains the major susceptibility locus for psoriatic disease. Future studies using next-generation sequencing technologies may reveal novel rare susceptibility genes for this disease.
More Related Videos
Related Concept Videos
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
Pharmacogenomics: Identification of New Drug Targets
Inflammatory Bowel Disease III: Crohn's Disease

